Herceptin
(Trastuzumab)ApprovedMonoclonal antibody
Trastuzumab is used to treat certain types of breast cancer and stomach cancer that have a specific protein called HER2 on their surface. It works by targeting and attacking cancer cells that have this protein, helping to slow or stop their growth.[2] Herceptin is currently approved and in use across 75 indications[4].[1]
Herceptin is one of 1014 monoclonal antibody programs targeting Ependymoma. It is currently in Approved.
75
Indications
940
Total Trials
70
Active Trials
1,013
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 75 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Herceptin
OOrganon and Co
Approved
Tykerb
GSKPreclinical
Avastin
BBio-Thera Solutions
Preclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Megace
Bristol-Myers SquibbPreclinical
DATROWAY
Daiichi SankyoPreclinical
Voltaren
NovartisPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Zinecard
CChildren's Oncology Group
Preclinical
Spravato
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer124 trials
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
Not yet recruiting·—·Phase 2·NCT05983094·181 enrolled
Show 121 more trials
DP303c in Patients With HER2-positive Advanced Breast Cancer
Not yet recruiting·
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT05901935·420 enrolled
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT05901935·420 enrolledCombination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00036868·90 enrolled
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer
Withdrawn·—·Phase 1/2·NCT00006123
Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial
Not yet recruiting·—·Phase 4·NCT06245824·51 enrolled
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Completed·—·Phase 2·NCT01847001·10 enrolled
Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
Completed·—·Phase 2·NCT02789657·32 enrolled
Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2/3·NCT05189067·190 enrolled
Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer
Terminated·—·Phase 2·NCT01912963·32 enrolled
Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer
Completed·—·Phase 3·NCT00146549·250 enrolled
Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients
Completed·—·Phase 2·NCT00429247·75 enrolled
Gastric Cancer7 trials
Show 4 more trials
Advanced Solid Tumors4 trials
Neoadjuvant Treatment3 trials
49 more indications
Paclitaxel3 trials
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Completed·—·Phase 2·NCT01853748·512 enrolled
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Completed·—·Phase 2·NCT01796197·23 enrolled
Treatment3 trials
Solid Tumors2 trials
Biliary Tract Cancer2 trials
Endocrine Therapy2 trials
Lymphoma1 trial
Locally Advanced1 trial
Liver1 trial
Left Ventricular Dysfunction1 trial
Salivary Gland Cancer1 trial
Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer
Completed·—·Phase 2·NCT00004163·14 enrolled
Abemaciclib1 trial
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
Withdrawn·—·Phase 1·NCT03846583
Lung Cancer1 trial
Gallbladder Cancer1 trial
HER2-Positive Solid Tumor1 trial
Metastatic Colorectal Cancer1 trial
Prophylaxis1 trial
Refractory to Standard Therapies1 trial
Monotherapy1 trial
First-line Treatment1 trial
Gastroesophageal Junction1 trial
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Active, not recruiting·—·Phase 2·NCT05480384·1 enrolled
Cancers1 trial
Capecitabine1 trial
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
Unknown status·—·Phase 2·NCT04309578·28 enrolled
Chemotherapy1 trial
Other Solid Tumors1 trial
Patients With Advanced Solid Tumors1 trial
Multiple Myeloma1 trial
Metastatic Prostate Cancer1 trial
Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
Completed·—·Phase 2·NCT00005857
Advanced Urothelial Cancer1 trial
Ductal Carcinoma in Situ1 trial
Malignancies1 trial
Cancer of the Pancreas1 trial
Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas
Unknown status·—·Phase 2·NCT00003797·41 enrolled
Growth1 trial
Esophageal Adenocarcinoma1 trial
Efficacy and Safety1 trial
Gastric Adenocarcinoma1 trial
Cardiotoxicity1 trial
Regulatory
FDA Approval Timeline[5]
Sep 25, 1998
Herceptin
BLA 103792
Sep 25, 1998
HERCEPTIN
BLA BLA103792
Dec 14, 2018
HERZUMA
BLA BLA761091
Jan 18, 2019
ONTRUZANT
BLA BLA761100
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Herceptin drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Trastuzumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- HER2 Inhibitor[3]
- Modality
- Monoclonal antibody[3]
- Highest Phase
- Approved[1]
- Company
- OOrganon and Co